Traditional modes of ventilation have failed to improve patient survival. Subsequent observations that elevated airway pressures observed in traditional forms of ventilation resulted in barotrauma and extension of ALI lead to the evolution of low volume cycled ventilation as a potentially better ventilatory modality for ARDS. Recent multicenter trials by the NIH-ARDS network have confirmed that low volume ventilation increases the number of ventilatory free days and improves overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.
Low volume ventilation may increase number of ventilatory free days and may improve overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
1. Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 \< 40% 2. Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min 3. Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg \& setting positive end-expiratory pressure (PEEP) based on level of initial FiO2 4. Inspiratory to Expiratory ratio set at 1:1 to 1:3 5. If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased 6. Mgmt of PEEP will be conducted as per the ARDSnet Protocol 7. Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95% 8. Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol
1. Ventilation uses Drager Model X1 2. Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels 3. Time periods for the high \& low pressure levels can be set independently 4. Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume 5. Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min 6. Spontaneous frequency will be targeted for 6 to 18 breaths/per min 7. If spontaneous breathing is achieved,level of sedation will be decreased 8. If spontaneous respirations are \>20 breaths/min, sedation will be increased 9. If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased
James A. Tumlin, MD
Chattanooga, Tennessee, United States
All cause mortality
Time frame: 28 days or prior to hospital discharge
Number of ventilator-free days
Time frame: 28 days or prior to hospital discarge
Length of ICU stay and /or Total hospital days
Time frame: 28 days or prior to hospital discharge
To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the incidence of of AKI
Time frame: 28 days or prior to hospital discharge
To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the NGAL, KIM-1, and IL-18 urine biomarkers for AKI
Time frame: 28 days or prior to hospital discharge
To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation in maintaining hourly urine output > 0.5 mls/kg/hr
Time frame: 28 days or prior to hospital discharge
Will determine urinary aquaporin-2 levels in patients randomized to APRV ventilation versus ARDS net low volume-cycle ventilation
Time frame: 28 days or prior to hospital discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.